© 2000 American Heart Association, Inc.
Molecular Medicine |
Probing the Interaction Between Inactivation Gating and Dd-Sotalol Block of HERG
From the Departments of Anesthesiology (H.N., J.R.B.) and Pharmacology (F.M.M., J.P.J., I.C.-H.Y., J.R.B.), Vanderbilt University School of Medicine, Nashville, Tenn, and Institute for Molecular Cardiobiology (S.S.P., G.F.T.), The Johns Hopkins University School of Medicine, Baltimore, Md.
Correspondence to Jeffrey R. Balser, MD, PhD, Room 560, MRB II, Vanderbilt University School of Medicine, Nashville, TN 37232. E-mail jeff.balser{at}mcmail.vanderbilt.edu
Abstract—Potassium channels encoded by HERG underlie IKr, a sensitive target for most class III antiarrhythmic drugs, including methanesulfonanilides such as Dd-sotalol. Recently it was shown that these drugs are trapped in the channel as it closes during hyperpolarization. At the same time, HERG channels rapidly open and inactivate when depolarized, and methanesulfonanilide block is known to develop in a use-dependent manner, suggesting a potential role for inactivation in drug binding. However, the role of HERG inactivation in class III drug action is uncertain: pore mutations that remove inactivation reduce block, yet many of these mutations also modify the channel permeation properties and could alter drug affinity through gating-independent mechanisms. In the present study, we identify a definitive role for inactivation gating in Dd-sotalol block of HERG, using interventions complementary to mutagenesis. These interventions (addition of extracellular Cd2+, removal of extracellular Na+) modify the voltage dependence of inactivation but not activation. In normal extracellular solutions, block of HERG current by 300 µmol/L Dd-sotalol reached 80% after a 10-minute period of repetitive depolarization to +20 mV. Maneuvers that impeded steady-state inactivation also reduced Dd-sotalol block of HERG: 100 µmol/L Cd2+ reduced steady-state block to 55% at +20 mV (P<0.05); removing extracellular Na+ reduced block to 44% (P<0.05). An inactivation-disabling mutation (G628C-S631C) reduced Dd-sotalol block to only 11% (P<0.05 versus wild type). However, increasing the rate of channel inactivation by depolarizing to +60 mV reduced Dd-sotalol block to 49% (P<0.05 versus +20 mV), suggesting that the drug does not primarily bind to the inactivated state. Coexpression of MiRP1 with HERG had no effect on inactivation gating and did not modify Dd-sotalol block. We postulate that Dd-sotalol accesses its receptor in the open pore, and the drug-receptor interaction is then stabilized by inactivation. Whereas deactivation traps the bound methanesulfonanilide during hyperpolarization, we propose that HERG inactivation stabilizes the drug-receptor interaction during membrane depolarization.
Key Words: HERG • potassium channel • inactivation • antiarrhythmic drugs
This article has been cited by other articles:
 |
|
 |
|
  T. Myokai, S. Ryu, H. Shimizu, and S. Oiki Topological Mapping of the Asymmetric Drug Binding to the Human Ether-a-go-go-Related Gene Product (HERG) Potassium Channel by Use of Tandem Dimers Mol. Pharmacol., June 1, 2008; 73(6): 1643 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zhang, J. Liu, and G.-N. Tseng Gating Charges in the Activation and Inactivation Processes of the hERG Channel J. Gen. Physiol., November 29, 2004; 124(6): 703 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Mullins, S. Z. Stepanovic, N. B. Gillani, A. L. George Jr, and J. R. Balser Functional interaction between extracellular sodium, potassium and inactivation gating in HERG channels J. Physiol., August 1, 2004; 558(3): 729 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Brugada, K. Hong, R. Dumaine, J. Cordeiro, F. Gaita, M. Borggrefe, T. M. Menendez, J. Brugada, G. D. Pollevick, C. Wolpert, et al. Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG Circulation, January 6, 2004; 109(1): 30 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wang, J. J. Salata, and P. B. Bennett Saxitoxin Is a Gating Modifier of hERG K+ Channels J. Gen. Physiol., May 27, 2003; 121(6): 583 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zhang, Y. V. Korolkova, J. Liu, M. Jiang, E. V. Grishin, and G.-N. Tseng BeKm-1 Is a HERG-Specific Toxin that Shares the Structure with ChTx but the Mechanism of Action with ErgTx1 Biophys. J., May 1, 2003; 84(5): 3022 - 3036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Mullins, S. Z. Stepanovic, R. R. Desai, A. L. George Jr., and J. R. Balser Extracellular Sodium Interacts with the HERG Channel at an Outer Pore Site J. Gen. Physiol., September 30, 2002; 120(4): 517 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chen, G. Seebohm, and M. C. Sanguinetti Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels PNAS, September 17, 2002; 99(19): 12461 - 12466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Pardo-Lopez, M. Zhang, J. Liu, M. Jiang, L. D. Possani, and G.-N. Tseng Mapping the Binding Site of a Human ether-a-go-go-related Gene-specific Peptide Toxin (ErgTx) to the Channel's Outer Vestibule J. Biol. Chem., May 3, 2002; 277(19): 16403 - 16411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ficker, C. A. Obejero-Paz, S. Zhao, and A. M. Brown The Binding Site for Channel Blockers That Rescue Misprocessed Human Long QT Syndrome Type 2 ether-a-gogo-related Gene (HERG) Mutations J. Biol. Chem., February 8, 2002; 277(7): 4989 - 4998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ficker, W. Jarolimek, and A. M. Brown Molecular Determinants of Inactivation and Dofetilide Block in ether a-go-go (EAG) Channels and EAG-Related K+ Channels Mol. Pharmacol., December 1, 2001; 60(6): 1343 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Thomas, G. Wendt-Nordahl, K. Röckl, E. Ficker, A. M. Brown, and J. Kiehn High-Affinity Blockade of Human Ether-A-Go-Go-Related Gene Human Cardiac Potassium Channels by the Novel Antiarrhythmic Drug BRL-32872 J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 753 - 761. [Abstract] [Full Text]
|
|